Leukemia, Acute, MDS
Conditions
Keywords
PBSCT, myeloablative conditioning, HDACi, chidamide
Brief summary
This study is to explore the efficacy and safety of introduction of chidamide in PTCy based GVHD prophylaxis in patients undergoing allogeneic PBSCT.
Detailed description
Eligible patients were aged 16 to 65 years, diagnosed with hematologic malignancy, and had a Karnofsky performance score of ≥70% and were candidates for myeloablative HCT. A 8/8 HLA allelic match between the donor and the recipient at HLA-A, HLA-B, HLA-C, and HLA-DRB1 by high-resolution typing was required. The graft source was PBSC. Patients received a myeloablative conditioning regimen consisting of oral chidamide given twice weekly at a dose of 20 mg from day -7 to 2 weeks post transplantation, intravenous busulfan 3.2 mg/kg from day -6 to -3, intravenous fludarabine 30 mg/m2 and cytarabine 1g/m2 respectively from day -6 to -2. PBSCs were infused on day 0. GVHD prophylaxis was post-transplantation cyclophosphamide (50 mg/kg on day +3, +4) and cyclosporine (started from day +5). In the absence of GVHD, cyclosporine tapering started on day +100 and discontinued on day +180. Minimal residual disease (MRD) was determined by multi-parameter flow cytometry.
Interventions
DRUGChidamide
20 mg orally, twice weekly from D-7 to D+14
DRUGCyclophosphamide
50 mg/Kg intravenously D+3, +4
DRUGcyclosporine A
3 mg/Kg intravenously then orally from D+5 to D+100 if no acute graft-versus-host disease
Sponsors
Sichuan University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
16 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 16 years or older, and ≤ 65 years at time of enrollment 2. Signed informed consent 3. Hematologic disorder requiring allogeneic hematopoietic cell transplantation 4. Left ventricular ejection fraction (LVEF) ≥ 45% by multiple uptake gated acquisition (MUGA) scan or echocardiogram 5. Forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and diffusing lung capacity oxygenation (DLCO) adjusted ≥ 50% of predicted values on pulmonary function tests 6. Transaminases (AST, ALT) \< 3 times upper limit of normal (ULN) values 7. Creatinine clearance calculated ≥ 50 mL/min 8. Karnofsky Performance Status Score ≥ 60%. 9. Human leukocyte antigen (HLA) matched 8/ (A, B, C, DRB1) related or unrelated donor
Exclusion criteria
1. Active infection not controlled with appropriate antimicrobial therapy HIV, hepatitis B (HBcAb positive but HBsAg negative with undetectable viral load are eligible), or hepatitis C infection 2. Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) ≥4 3. Anti-thymocyte globulin (ATG) as part of the conditioning regimen 4. Pregnancy 5. Histone deacetylase (HDAC), DAC, HSP90 inhibitors or valproic acid for the treatment of cancer within 30 days 6. Patients who will need valproic acid for any medical condition during the study or within 5 days prior to first chidamide treatment 7. Impaired cardiac function or clinically significant cardiac diseases, including any one of the following: Any history of ventricular fibrillation or torsade de pointes; Bradycardia defined as heart rate (HR)\< 45 bpm (Patients with pacemakers are eligible if HR ≥ 45 bpm); Screening electrocardiogram (ECG) with a QTcF \> 480 msec; Right bundle branch block + left anterior hemiblock (bifascicular block); Patients with myocardial infarction or unstable angina ≤ 12 months prior to starting study drug; Other clinically significant heart disease (e.g., New York Heart Association (NYHA) class III or IV , uncontrolled hypertension) as per discretion of principal investigator and/or treating physician; Patients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting study drug with the exception of drugs listed on Appendix B of study documents that are required for hematopoietic cell transplantation (HCT) patients.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| aGVHD | 100 day after infusion of PBSCs | accumulated incidence of aGVHD |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| GRFS | 3 years after recruitment | GVHD free, relapse free survival |
| DFS | 3 years after recruitment | Disease free survival |
| OS | 3 years after recruitment | Overall survival |
| cGVHD | 2 yeas after infusion of PBSCs | accumulated incidence of cGVHD |
Countries
China
Contacts
Primary ContactJie Ji, MD
Backup ContactTing Liu, MD PHD
Outcome results
None listed